508 related articles for article (PubMed ID: 34650994)
1. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.
Bruneau A; Hundertmark J; Guillot A; Tacke F
Front Med (Lausanne); 2021; 8():725390. PubMed ID: 34650994
[TBL] [Abstract][Full Text] [Related]
2. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease.
Hundertmark J; Krenkel O; Tacke F
Front Immunol; 2018; 9():2418. PubMed ID: 30405618
[TBL] [Abstract][Full Text] [Related]
3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
4. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.
Arab JP; Arrese M; Shah VH
Hepatol Res; 2020 Apr; 50(4):407-418. PubMed ID: 31840358
[TBL] [Abstract][Full Text] [Related]
6. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.
Poeta M; Pierri L; Vajro P
Children (Basel); 2017 Aug; 4(8):. PubMed ID: 28767077
[TBL] [Abstract][Full Text] [Related]
7. Gut-liver axis: Pathophysiological concepts and clinical implications.
Tilg H; Adolph TE; Trauner M
Cell Metab; 2022 Nov; 34(11):1700-1718. PubMed ID: 36208625
[TBL] [Abstract][Full Text] [Related]
8. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
9. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
Villard A; Boursier J; Andriantsitohaina R
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
[TBL] [Abstract][Full Text] [Related]
10. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
Frasinariu OE; Ceccarelli S; Alisi A; Moraru E; Nobili V
Dig Liver Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23280158
[TBL] [Abstract][Full Text] [Related]
11. Gut-liver axis: role of inflammasomes.
Bawa M; Saraswat VA
J Clin Exp Hepatol; 2013 Jun; 3(2):141-9. PubMed ID: 25755488
[TBL] [Abstract][Full Text] [Related]
12. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
13. Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.
Li ZJ; Gou HZ; Zhang YL; Song XJ; Zhang L
World J Gastroenterol; 2022 Nov; 28(44):6213-6229. PubMed ID: 36504550
[TBL] [Abstract][Full Text] [Related]
14. [The gut-liver axis: how the gut promotes liver disease].
Demir M; Tacke F
Inn Med (Heidelb); 2022 Oct; 63(10):1028-1035. PubMed ID: 36053302
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
16. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
[TBL] [Abstract][Full Text] [Related]
17. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
18. Host-Microbiota Interactions in Liver Inflammation and Cancer.
Giraud J; Saleh M
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503151
[TBL] [Abstract][Full Text] [Related]
19. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy.
Bozward AG; Ronca V; Osei-Bordom D; Oo YH
Front Immunol; 2021; 12():711217. PubMed ID: 34512631
[TBL] [Abstract][Full Text] [Related]
20. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
